Elyxium Wealth’s Mineralys Therapeutics MLYS Stock Holding History

Elyxium Wealth’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.65K	Buy	+225	New	+$6.12K	﹤0.01%	1145

Other funds holding MLYS

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Elyxium Wealth's MLYS Position: Q3 2026 in Review

Elyxium Wealth opened a new position in Mineralys Therapeutics (MLYS) in Q3 2026: 225 shares worth $5.65K. The stake represents ﹤0.01% of the portfolio and ranks #1145 among its holdings.

27 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

Elyxium Wealth held 225 shares of Mineralys Therapeutics worth $5.65K as of Q3 2026.
Mineralys Therapeutics was a new Elyxium Wealth position in Q3 2026.
Mineralys Therapeutics made up ﹤0.01% of Elyxium Wealth's portfolio in Q3 2026, its #1145 holding.
27 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Elyxium Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.